CL2009001486A1 - Uso de compuestos derivados de fenilaminopirimidina para tratar neurofibroma plexiforme. - Google Patents

Uso de compuestos derivados de fenilaminopirimidina para tratar neurofibroma plexiforme.

Info

Publication number
CL2009001486A1
CL2009001486A1 CL2009001486A CL2009001486A CL2009001486A1 CL 2009001486 A1 CL2009001486 A1 CL 2009001486A1 CL 2009001486 A CL2009001486 A CL 2009001486A CL 2009001486 A CL2009001486 A CL 2009001486A CL 2009001486 A1 CL2009001486 A1 CL 2009001486A1
Authority
CL
Chile
Prior art keywords
phenylaminopyrimidine
treat
derived compounds
plexiform neurofibroma
neurofibroma
Prior art date
Application number
CL2009001486A
Other languages
English (en)
Inventor
Clapp
wade D
David Ingram
feng-chun Yang
Original Assignee
Univ Indiana Res & Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41445287&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009001486(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Indiana Res & Tech Corp filed Critical Univ Indiana Res & Tech Corp
Publication of CL2009001486A1 publication Critical patent/CL2009001486A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Método para tratar neurofibroma plexiforme con un compuesto derivado de pirimidina.
CL2009001486A 2008-06-27 2009-06-25 Uso de compuestos derivados de fenilaminopirimidina para tratar neurofibroma plexiforme. CL2009001486A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7618508P 2008-06-27 2008-06-27
US10365008P 2008-10-08 2008-10-08

Publications (1)

Publication Number Publication Date
CL2009001486A1 true CL2009001486A1 (es) 2010-04-16

Family

ID=41445287

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001486A CL2009001486A1 (es) 2008-06-27 2009-06-25 Uso de compuestos derivados de fenilaminopirimidina para tratar neurofibroma plexiforme.

Country Status (18)

Country Link
US (3) US20110195975A1 (es)
EP (1) EP2291186A4 (es)
JP (2) JP2011526292A (es)
KR (2) KR20160011713A (es)
CN (2) CN102099038A (es)
AU (1) AU2009262214B9 (es)
BR (1) BRPI0914618A2 (es)
CA (1) CA2727737C (es)
CL (1) CL2009001486A1 (es)
EA (2) EA022611B1 (es)
IL (1) IL209973A (es)
MA (1) MA32419B1 (es)
MX (1) MX2010013918A (es)
NZ (1) NZ590076A (es)
SG (1) SG192444A1 (es)
TW (1) TWI508728B (es)
WO (1) WO2009158447A2 (es)
ZA (1) ZA201009066B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ630363A (en) 2012-07-25 2018-09-28 Celldex Therapeutics Inc Anti-kit antibodies and uses thereof
CN113975386A (zh) * 2014-05-23 2022-01-28 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
KR101894769B1 (ko) 2017-12-05 2018-09-04 아주대학교산학협력단 siRNA를 포함하는 신경섬유육종 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
GB0022438D0 (en) * 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
CA2439440A1 (en) * 2002-09-05 2004-03-05 Emory University Treatment of tuberous sclerosis associated neoplasms
WO2007065898A1 (en) * 2005-12-06 2007-06-14 Novartis Ag Pyrimidylaminobenzamide derivatives for the treatment of neurofibromatosis
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
MA32419B1 (fr) 2011-06-01
NZ590076A (en) 2012-11-30
JP2015187104A (ja) 2015-10-29
EA022611B1 (ru) 2016-02-29
TWI508728B (zh) 2015-11-21
WO2009158447A9 (en) 2010-03-25
IL209973A (en) 2015-11-30
WO2009158447A2 (en) 2009-12-30
AU2009262214B2 (en) 2014-12-11
KR20160011713A (ko) 2016-02-01
US20110195975A1 (en) 2011-08-11
CN105726542A (zh) 2016-07-06
EA201500525A1 (ru) 2015-11-30
MX2010013918A (es) 2011-07-04
EA201071340A1 (ru) 2011-12-30
US8933082B2 (en) 2015-01-13
US20140121214A1 (en) 2014-05-01
AU2009262214B9 (en) 2015-04-30
CN102099038A (zh) 2011-06-15
KR20110044945A (ko) 2011-05-03
CA2727737A1 (en) 2009-12-30
ZA201009066B (en) 2011-08-31
IL209973A0 (en) 2011-02-28
JP2011526292A (ja) 2011-10-06
US20150072992A1 (en) 2015-03-12
SG192444A1 (en) 2013-08-30
BRPI0914618A2 (pt) 2017-06-06
TW201006472A (en) 2010-02-16
AU2009262214A1 (en) 2009-12-30
EP2291186A4 (en) 2011-06-22
CA2727737C (en) 2016-08-23
EP2291186A2 (en) 2011-03-09
US9345704B2 (en) 2016-05-24

Similar Documents

Publication Publication Date Title
ES2570569T3 (es) Compuestos de benzoxazepina como inhibidores de la PI3K y métodos de uso
UA110338C2 (xx) Хімічні сполуки
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
CL2011000134A1 (es) Compuestos derivados de aminofenoxiindazoles, inhibidores de c-met; composicion farmaceutica que comprende a estos compuestos; y su uso para tratar el cancer.
BRPI0921433A2 (pt) uso de anticorpos anti-cs1 para o tratamento de linfomas raros
CR20140024A (es) Compuestos inhibidores de metaloenzimas
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
CO6842020A2 (es) Inhibidores de la tirosina-quinasa de bruton
CL2007001670A1 (es) Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas.
EA201171396A1 (ru) Лечение портальной гипертензии и восстановление функции печени с помощью l-орнитинфенилацетата
UY31770A1 (es) Inhibidores de catepsina c
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
BRPI1010937A2 (pt) composto, uso de um composto, e, método para tratar câncer
DK2293816T3 (da) Fremgangsmåder til behandling af reumatoid arthritis
MA32551B1 (fr) Nouveaux composes utiles pour le traitement de maladies degeneratives et inflammatoires
CR11020A (es) Compuestos amino-5-[-4-(difluorometoxi)fenil suatituido]-5-fenilimidazolona como inhibidores de b-secretasa
CL2010001530A1 (es) Compuestos derivados de tiadiazoliloxifenilamidinas; su procedimiento de preparacion; agentes para combatir microorganismos indeseados que comprende a dichos compuestos; uso; procedimiento para combatir microorganismos indeseados; y compuestos intermediarios.
EA201170832A1 (ru) Пуриновые соединения
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
EA201170288A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
BR112012020113A2 (pt) compostos de ligação ao domínio iap bir
ECSP12012354A (es) Compuestos heterocíclicos, su preparación y su aplicación terapéutica